A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Trial status:Recruitment Complete
Trial ID:
NTC-001
NCT ID:
EudraCT ID:
EU Trial (CTIS) Number:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech US Inc.
Recruitment Complete
Trial Details
This study will investigate the safety and activity of NEO-PTC-01 in patients with unresectable or metastatic melanoma. NEO-PTC-01 is an autologous personalized T cell (PTC) product for adoptive cell therapy that is manufactured ex vivo and targets neoantigens displayed on the patient's tumor and the tumor microenvironment.
The study will be conducted in two parts, Part 1 (Dose Finding) and Part 2 (Dose Expansion).
Medical Condition
Trial Drug
See more
Phase
Phase 1
Type
Interventional
Estimated Enrolment
22
Estimated Trial Date
Dec 2020 - Dec 2029
Trial Participant Requirements
Age
18 - 75 Years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Universitair Ziekenhuis Brussel
Brussel, Belgium, 1090
Status
Location
Netherlands Cancer Institute - Antoni van Leeuwenhoek
Amsterdam, Netherlands, 1066 CX
Status